ProPhase Labs, Inc.
PRPH · OTCMCIK 868278fmd_0T89WWKK9B90Z88DXJ58MK8N9SManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Jun 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 4 | 10 | 13 | 10 | 15 | 79 | 123 | 35 | 7 | 4 |
| Rental revenue | – | – | – | – | – | – | – | – | – | – |
| Cost of revenue | 3 | 8 | 8 | 7 | 10 | 37 | 52 | 19 | 7 | 3 |
| Net interest income | (0) | 0 | 0 | – | – | – | – | – | – | – |
| Gross profit | 1 | 2 | 5 | 3 | 5 | 42 | 71 | 16 | (0) | 1 |
| Realized investment gains (losses) | – | – | – | – | – | (0) | (0) | 0 | – | – |
| Provision for credit losses | – | – | – | – | – | – | 6 | 0 | 0 | – |
| Research and development | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Selling, general and administrative | 4 | 6 | 6 | 6 | 8 | – | – | – | – | – |
| Gain on sale of real estate | – | – | – | – | 2 | – | 0 | 0 | 0 | – |
| Total operating expenses | 5 | 6 | 6 | 6 | 9 | 32 | 47 | 37 | 38 | 19 |
| Operating income | (3) | (4) | (2) | (3) | (2) | 10 | 24 | (21) | (39) | (18) |
| Interest expense | 0 | 0 | – | – | 0 | 1 | 1 | 1 | 3 | 7 |
| Interest and investment income | (0) | 0 | 0 | 0 | 0 | 1 | 0 | – | – | – |
| Other non-operating income (expense) | 0 | 0 | – | – | – | – | 0 | 0 | (0) | (0) |
| Income before taxes | (4) | (4) | (1) | (3) | (2) | 5 | 23 | (22) | (42) | (23) |
| Income tax expense | – | (1) | 0 | – | 0 | (1) | 4 | (6) | 7 | 0 |
| Net income from continuing operations | (4) | (2) | (2) | (3) | (2) | 6 | 18 | (16) | (50) | (23) |
| Net income | (3) | 41 | (2) | (3) | (2) | 6 | 18 | (17) | (53) | (15) |
| Net income to common shareholders | – | – | – | – | (2) | 6 | 18 | (17) | – | – |